Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes
It has been reported to cause jaundice, fulminant hepatitis, subacute hepatic necrosis, cholestatic hepatitis and acute liver failure [216,217]
Used as forever therapy, they are something else, and we will get into that on a separate post
While we strive to ensure the label information on this site represents the label on the product available for purchase, products are updated from time to time
What Lifestyle and Diet Changes Are Required While Taking This Medication
What preclinical research areas commonly reference BPC-157